Scientific deep-dive
What GIP Does on Its Own
Tirzepatide's advantage is usually credited to its GIP component. Researchers infused native GIP for six weeks, raising total GIP in the blood about thirtyfold, and blood sugar did not improve.
Tirzepatide acts on two receptors, and its advantage over drugs acting on one is usually credited to the second: GIP. Researchers infused native GIP for six weeks, alone and on top of semaglutide, raising total GIP in the blood roughly thirtyfold. Blood sugar did not improve.[1] That is the second study to find GIP doing very little for glucose in people, and it leaves an open question about why tirzepatide works.
What was done
Sixty-one people with type 2 diabetes were randomized into four groups (placebo alone, GIP alone, semaglutide alone, and semaglutide plus GIP) for six weeks of continuous subcutaneous infusion, double-blind.
The exposure achieved was not marginal. Fasting bioactive GIP rose from around 7 pmol/L on placebo to 45 on GIP alone and 85 alongside semaglutide; total GIP went from 14 to 375 and 527 respectively. Whatever this study failed to find, it did not fail for want of drug.
| Comparison | Estimated effect | 97.5% CI | P |
|---|---|---|---|
| GIP vs placebo | +0.80 mmol/L | −0.18 to 1.80 | 0.13 |
| GIP added to semaglutide | +0.05 mmol/L | −0.85 to 0.95 | 1.00 |
The trial had set a target of a 1.50 mmol/L improvement, and neither comparison came close. The second row is as flat a result as this kind of analysis produces, with a P value of 1.00 and an interval sitting symmetrically around zero.
Thirty times the total GIP in the blood, and the glucose line did not move.
The second study to say this
We covered a phase 1 trial of a long-acting GIP receptor agonist, which produced dose-dependent weight loss but whose effect on fasting glucose was transient and no longer significantly different from placebo by day 29. That is in the drugs that are not here yet.
This matters because GIP is an incretin, a hormone named for its ability to stimulate insulin release after eating. Its glucose-lowering role is the reason anyone was interested in it. In people with type 2 diabetes, it appears not to deliver that. Its clearest effect may lie outside the pancreas: in people whose pancreas had been removed, blocking the GIP receptor blunted the drop in bone breakdown after a meal.
So what is tirzepatide's GIP component doing?
This is the question the result raises and does not answer. Tirzepatide beats semaglutide substantially on weight (20.2% against 13.7% in the head-to-head), and the dual mechanism is the usual explanation. If GIP does nothing, the explanation needs revisiting.
- It may act on weight rather than glucose. The long-acting agonist study found exactly that pattern: weight loss without a durable glycemic effect. This trial measured glucose.
- A long-acting agonist is not the native hormone. Engineered molecules can differ from natural ligands in how strongly they bind, how long they stay and how the receptor responds. Those differences change the biology.
- A continuous infusion is not a physiological signal. GIP is released in pulses after meals. Flooding the system steadily may not reproduce what pulses do.
- The receptor may be desensitized in type 2 diabetes, which is a long-standing hypothesis and would explain a null in exactly this population.
None of those is established. The GIP contribution to tirzepatide is less well understood than the confident explanations suggest. Amgen’s experimental MariTide makes the puzzle sharper: it blocks the GIP receptor and still produced large weight loss in phase 2 (see MariTide: what the evidence shows).
What limits the trial
- Sixty-one people at a single center over six weeks, with 16% discontinuing. The authors state that the dropouts constrain what they can conclude.
- Every participant self-reported as White, which is the systematic pattern set out in who was actually in the trials.
- It measured glucose, not weight. A null on one endpoint is not a null on the other.
- Median diabetes duration was 6.3 years with a median HbA1c of 54 mmol/mol, which is reasonably controlled disease with less room to improve.
Injection site reactions were the commonest adverse event at 36%, which is what a six-week continuous infusion produces and not a property of the hormone.
Frequently Asked Questions
References
- 1.Helsted MM, Fonnesbech-Wulff C, Schaltz NL, et al. Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial The Lancet Diabetes & Endocrinology. 2026. PMID: 42173109.
Compare the sellers
Related research
A Weight Drug for Having Too Little Fat
Lipodystrophy is the opposite of obesity: people are missing fat tissue, and are severely metabolically ill because of it. In a cohort given tirzepatide, those with familial partial lipodystrophy cut their daily insulin by a median of 109 units.
6 min read
The Top Dose Keeps Not Being Worth It
Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.
7 min read
A Composite Is Only Its Components
A reanalysis found tirzepatide getting far more patients to three or more treatment targets. The comparator was semaglutide at 1 mg, and the gap was carried by two of the four targets.
7 min read
One Injection Instead of Twenty-Eight
Someone on basal-bolus insulin injects roughly 28 times a week. A trial tested replacing that with one weekly combination injection, matching blood sugar control while cutting serious hypoglycemia by 88%.
6 min read
Tirzepatide in Ten- to Seventeen-Year-Olds
Youth-onset type 2 diabetes moves faster and responds worse than the adult disease. In 99 children aged 10 to 17, tirzepatide cut HbA1c by 2.23% while the placebo group's blood sugar rose.
6 min read
A Quarter the Odds of Being Offered It
People with diabetes who also have a mental health diagnosis received worse care on almost every measure, and a quarter of the odds of being prescribed a GLP-1, while having half again the odds of being put on insulin.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →MyDrHank
An oral route if you will not self-inject
From $171/mo, prepaid
Get started →